Details for Patent: 8,778,947
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,778,947 protect, and when does it expire?
Patent 8,778,947 protects ESBRIET and is included in two NDAs.
This patent has seventeen patent family members in fifteen countries.
Summary for Patent: 8,778,947
Title: | Methods of administering pirfenidone therapy |
Abstract: | The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly. |
Inventor(s): | Bradford; Williamson Z. (Wilson, WY) |
Assignee: | Intermune, Inc. (Brisbane, CA) |
Application Number: | 14/015,857 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,778,947 |
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 8,778,947
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN | See Plans and Pricing | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER | See Plans and Pricing | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER | See Plans and Pricing | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER | See Plans and Pricing | ||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER | See Plans and Pricing | ||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,778,947
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2013308489 | See Plans and Pricing | |||
Brazil | 112015004499 | See Plans and Pricing | |||
Canada | 2819967 | See Plans and Pricing | |||
China | 104780762 | See Plans and Pricing | |||
European Patent Office | 2702994 | See Plans and Pricing | |||
European Patent Office | 3143997 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |